PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA).
“This acquisition is a highly strategic move to enable us to achieve our aspirations to become a global leader and innovator of implant-based breast reconstruction (IBBR) procedures,” said Robert T. Davis, Jr., executive vice president and president, Tissue Technologies, Integra Life Sciences. “We are looking forward to working with SIA colleagues to continue pursuing our mission to improve patient outcomes.”
About Integra LifeSciences
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, BioD™, CerebroFlo®, CereLink® Certas® Plus, Codman®, CUSA®, Cytal®, DuraGen®, DuraSeal®, Gentrix®, ICP Express®, Integra®, Licox®, MAYFIELD®, MediHoney®, MicroFrance®, MicroMatrix®, NeuraGen®, PriMatrix®, SurgiMend®, TCC-EZ® and VersaTru®. For the latest news and information about Integra and its products, please visit integralife.com.
